3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
57
Breast Neoplasms
34
Neoplasms
31
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Multiple Myeloma
20
Recurrence
19
Leukemia, Myeloid, Acute
19
Neoplasm Metastasis
17
Colorectal Neoplasms
16
Lymphoma, Non-Hodgkin
15
Melanoma
13
Leukemia, Lymphocytic, Chronic, B-Cell
13
Leukemia
13
Carcinoma, Renal Cell
13
Ovarian Neoplasms
12
Lymphoma, Follicular
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Myelodysplastic Syndromes
11
Urinary Bladder Neoplasms
10
Lung Neoplasms
10
Lymphoma, Mantle-Cell
9
Lymphoma, Large B-Cell, Diffuse
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Hematologic Neoplasms
9
Carcinoma, Hepatocellular
9
Adenocarcinoma
9
Stomach Neoplasms
8
Small Cell Lung Carcinoma
8
Prostatic Neoplasms
8
Lymphoma, B-Cell, Marginal Zone
8
Interventions
cabozantinib
1
Ramucirumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Has announcements
×
Liver Neoplasms
×
Clear all
NCT02435433
2023-01-20
REACH-2
Eli Lilly and Company
Phase 3
Completed
399 enrolled
22 charts
1 FDA
NCT01908426
2021-05-06
CELESTIAL
Exelixis
Phase 3
Completed
707 enrolled
20 charts
1 FDA